No. of trials | Chlorpromazine | Placebo | RR (95% CI) Random | |
---|---|---|---|---|
events/total participants | ||||
General symptoms | ||||
Sedation | 18 | 224/725 | 68/517 | 2.30 (1.7–3.1) |
Weight gain > 10 lb; 4.5 Kg | 5 | 31/75 | 7/90 | 4.44 (2.1–9.3) |
Extrapyramidal symptoms | ||||
Acute dystonia | 4 | 28/472 | 5/306 | 3.10 (1.3–7.7) |
Parkinsonism | 12 | 123/723 | 40/542 | 2.60 (1.2–5.4) |
Fits | 3 | 19/450 | 4/245 | 2.41 (0.4–16.4) |
Akathisia | 8 | 53/602 | 40/400 | 0.95 (0.5–1.9) |
Allergic-type symptoms | ||||
Agranulocytosis/leucopenia | 7 | 10/207 | 2/187 | 2.02 (0.7–5.6) |
Rashes/itching | 11 | 42/658 | 21/475 | 1.43 (0.9–2.4) |
Jaundice | 3 | 8/116 | 1/115 | 4.04 (0.9–17.9) |
Photosensitivity | 6 | 81/496 | 9/303 | 5.19 (2.7–9.8) |
Eye opacity | 2 | 97/431 | 16/226 | 3.09 (1.9–5.1) |
Anti-cholinergic/nor-adrenergic symptoms | ||||
Hypotension + dizziness | 15 | 113/708 | 38/524 | 1.90 (1.4–2.7) |
Constipation | 9 | 40/590 | 16/365 | 1.68 (0.9–2.9) |
Urinary retention | 3 | 11/459 | 5/253 | 1.49 (0.5–4.3) |
Dry mouth | 5 | 32/473 | 4/283 | 4.00 (1.6–9.8) |
Blurred vision | 6 | 10/529 | 9/381 | 1.10 (0.5–2.9) |